Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study

Frontiers in Neurology

Neurology

Mirko Filippetti¹  Alessandro Picelli¹  Lorenza Scotti²  Stefano Paolucci³  Marzia Millevolte⁴  Carmelo Chisari⁵  Stefania Dalise⁵  Valentina Azzollini⁵  Michela Cosma⁶  Daria Cuneo⁷  Marco Invernizzi⁸  Marco Battaglia⁹  Alessio Baricich⁹  Lucia Cosenza^1,10  Nicoletta Cinone^1,11  Stefania Spina^1,11  Andrea Santamato^1,11 

[1] Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy;Department of Translational Medicine, Unit of Medical Statistics, Università del Piemonte Orientale, Novara, Italy;IRCCS Fondazione Santa Lucia, Rome, Italy;Neurorehabilitation Clinic, Department Neurological Sciences, University Hospital of Ancona, Ancona, Italy;Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy;Neuroscience and Rehabilitation Department, Ferrara University Hospital, Ferrara, Italy;Physical and Rehabilitation Medicine, A.S.L. Vercelli, Vercelli, Italy;Physical and Rehabilitation Medicine, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy;Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Translational Medicine, “Santi Antonio e Biagio e Cesare Arrigo” National Hospital, Alessandria, Italy;Physical and Rehabilitation Medicine, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy;Physical and Rehabilitation Medicine, “Ospedale Maggiore della Carità” University Hospital, Novara, Italy;Rehabilitation Unit, Department of Rehabilitation, “Santi Antonio e Biagio e Cesare Arrigo” National Hospital, Alessandria, Italy;Spasticity and Movement Disorder Unit, Physical Medicine and Rehabilitation, Policlinico Riuniti, University of Foggia, Foggia, Italy;

关键词: botulinum toxin;    pain;    spasticity;    movement disorders;    multiple sclerosis;    spinal cord injury;    traumatic brain injury;    rehabilitation;   

DOI  :  10.3389/fneur.2023.1133390

 received in 2022-12-28, accepted in 2023-03-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs.Clinical trial identifierNCT04673240.

【 授权许可】

Unknown   
Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato.